Trupanion, INC

Trupanion announced its second quarter 2026 financial results, showcasing an 11% increase in total revenue to $392.9 million, alongside the authorization of a significant $100 million share repurchase program.

Trupanion, Inc. announced the results of its 2026 Annual Meeting, including the election of nine directors, ratification of Ernst & Young LLP as auditor, and approval of executive compensation.

Trupanion, Inc. announced that board member Max Brodn will not stand for re-election at the upcoming 2026 Annual Meeting.

Trupanion, a leading pet medical insurance provider, announced robust financial results for the fourth quarter and full year ended December 31, 2025, achieving its 15% annual margin target.

Trupanion announced record quarterly profitability and accelerated subscription pet growth for Q3 2025, alongside securing a new $120 million credit facility with PNC Bank at a lower interest rate.

Trupanion, Inc. announced the appointment of Bradley S. Powell, former CFO of Expeditors International, to its Board of Directors, enhancing financial and strategic oversight.

Trupanion, Inc. announced its second quarter 2026 financial results, showcasing an 11% increase in total revenue driven by its subscription business, alongside strategic investments in growth and operational efficiencies.

Trupanion, Inc. reported a significant turnaround to net income for Q3 and the first nine months of 2025, driven by strong subscription business growth and strategic financial moves.

Trupanion, Inc. reported a return to net income and significant operating cash flow growth in Q2 2025, driven by strong subscription business performance.

Trupanion's Q1 2025 revenue increased by 12% year-over-year, driven primarily by growth in its subscription business segment.

Trupanion's Q3 2024 results show a 15% increase in total revenue, driven by subscription growth and strategic investments, despite ongoing challenges with internal controls.

Trupanion's Q2 2024 results show a revenue increase of 16% year-over-year, but the company continues to operate at a loss.

Trupanion, Inc. reported a significant financial turnaround in 2025, achieving net income of $19.4 million driven by robust subscription business growth and improved operating margins.

Trupanion's 2024 10-K filing reveals a year of significant revenue growth, reaching $1.3 billion, while navigating challenges in profitability and strategic shifts in its business segments.

Trupanion's 2023 annual report provides a comprehensive overview of the company's financial performance, capital structure, and risk factors, highlighting both growth and challenges in the pet insurance market.

Margaret Tooth, CEO and a Director of Trupanion, Inc., sold 978 shares of common stock on August 11, 2026 for $29.05 per share.

John R Gallagher, Chief Operating Officer of Trupanion, Inc., sold 431 shares of common stock on July 28, 2026 for $25.08 per share.

Trupanion, Inc. Chief Operating Officer John R. Gallagher sold 431 shares of common stock for $25.35 per share, as part of a pre-arranged trading plan.

Trupanion EVP Steve Weinrauch exercised 8,500 stock options and sold 6,674 shares of common stock.

EVP Simon Wheeler filed an amendment to correct clerical errors regarding the reporting of restricted stock unit holdings.

EVP Simon Wheeler filed an amendment to correct clerical errors regarding his restricted stock unit holdings in Trupanion, Inc.

Trupanion, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 10, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Trupanion's 2024 shareholder letter highlights the company's focus on sustainable growth, strategic investments in veterinary partnerships, and efforts to enhance member retention amidst veterinary inflation.

Trupanion, Inc. will hold its annual stockholder meeting on June 11, 2025, to vote on the election of directors, ratification of the accounting firm, and executive compensation.

Trupanion's 2025 proxy statement outlines key proposals for the annual meeting, including director elections, auditor ratification, and advisory votes on executive compensation.

Trupanion, Inc. has filed a definitive proxy statement with the SEC.

Trupanion's upcoming annual meeting will address director elections, equity incentive plan approval, accounting firm ratification, and executive compensation.

The Vanguard Group has reported 0% beneficial ownership in Trupanion Inc. following an internal realignment that disaggregated reporting to its subsidiaries.

Tarmac DLTFM Ltd has filed an amendment to its Schedule 13G, reporting zero beneficial ownership in Trupanion, Inc. common stock.

Felix Holdings BV has reported a 9.89% beneficial ownership stake in Trupanion, Inc., holding 4,296,538 shares of common stock.

Tarmac DLTFM Ltd. has reported an 8.3% beneficial ownership in Trupanion, Inc., holding 3,575,538 common shares as of its latest filing.

Wellington Management Group LLP and its affiliates reported a 4.8% beneficial ownership stake in Trupanion, Inc. common stock.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 5.2% in Trupanion, Inc.'s common stock as of December 31, 2024.